AWS
AMRX icon

Atria Wealth Solutions’s Amneal Pharmaceuticals AMRX Stock Holding History

Atria Wealth Solutions’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-31,700
Closed -$44.1K – 1866
2023
Q1 		$44.1K Sell
31,700
-4,000
-11% -$7.96K ﹤0.01% 1811
2022
Q4 		$71K Sell
35,700
-1,500
-4% -$3.36K ﹤0.01% 1715
2022
Q3 		$75.1K Buy
+37,200
New +$104K ﹤0.01% 1665
2022
Q2 		– Sell
-18,000
Closed -$75K – 1636
2022
Q1 		$75K Buy
+18,000
New +$79.7K ﹤0.01% 1683

Other funds holding AMRX

FI
Fosun International Hong Kong, China $446M AUM 13.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
EP
Eversept Partners New York $1.93B AUM 160.8% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Atria Wealth Solutions's AMRX Position: Q2 2023 in Review

Atria Wealth Solutions sold out of Amneal Pharmaceuticals (AMRX) in Q2 2023, closing a stake of 31,700 shares — an estimated $44.1K sold.

Atria Wealth Solutions first reported a position in AMRX in Q1 2022 and held it in 4 quarters. The position peaked at $75.1K in Q3 2022. 128 funds tracked by Wall St. Rank hold AMRX as of Q2 2023.

  • Atria Wealth Solutions reported no remaining Amneal Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Atria Wealth Solutions sold 31,700 Amneal Pharmaceuticals shares in Q2 2023, an estimated $44.1K.
  • Atria Wealth Solutions first reported a position in Amneal Pharmaceuticals in Q1 2022 and held it in 4 quarters.
  • Atria Wealth Solutions's Amneal Pharmaceuticals position peaked at $75.1K in Q3 2022.
  • 128 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2023.

Based on Atria Wealth Solutions's 13F filing for Q2 2023, filed 3 Aug 2023.